Septerna, Inc. Common Stock (SEPN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $38.14 (-3.44%), Market cap $1.21B, 52-week low–high $9.06 ~ $30.86.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular di
Financial statements, price targets, institutional (13F) holdings and related news for Septerna, Inc. Common Stock are updated in real time on BlackAll Trade.
Septerna, Inc. Common Stock trades at $38.14 (-3.44%). Real-time quotes and charts are available on BlackAll Trade.
Septerna, Inc. Common Stock has a market cap of about $1.21B.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflamm